What is Rejoni?
Rejoni, Inc. operates at the intersection of advanced materials science and clinical gynecology. By leveraging proprietary biomaterials, the company is developing a pipeline of medical products designed to address significant unmet needs in women's health. The firm's market position is bolstered by a robust network of strategic partners and institutional backers who provide both the financial runway and the industry expertise necessary to navigate the complex regulatory and clinical landscapes of the MedTech industry. Rejoni's focus remains on delivering high-impact, patient-centered solutions that improve clinical outcomes.
How much funding has Rejoni raised?
Rejoni has raised a total of $65M across 3 funding rounds:
Series A
$15M
Series B
$25M
Other Financing Round
$25M
Series A (2020): $15M with participation from Delos Capital, Sparta Group, and Ascension Ventures
Series B (2022): $25M led by Iyengar Capital Partners, Ascension, Sparta Group, Delos Capital, Amed Ventures, and Catalyst Health Ventures
Other Financing Round (2026): $25M supported by Iyengar Capital Partners, Delos Capital, ClavystBio, FemHealth Ventures, Amed Ventures, Catalyst Health Ventures, Ascension Ventures, and Sparta Group
Key Investors in Rejoni
Delos Capital
Delos Capital is a private equity firm based in New York City that specializes in private investment and financial advisory services, focusing on complex transactions and strategic alignment.
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm that invests on behalf of leading community health systems to support companies transforming the healthcare industry.
Catalyst Health Ventures
Catalyst Health Ventures is a venture capital firm focused on investing in transformative medical technologies that address global unmet healthcare needs through strategic insight and mentorship.
What's next for Rejoni?
With the successful closure of this major strategic investment, Rejoni is well-positioned to scale its operations and advance its product development roadmap. The company is expected to prioritize the clinical validation and market entry of its core biomaterial-based offerings. By maintaining its focus on high-growth segments within the gynecological market, Rejoni aims to solidify its competitive advantage. The continued support from its diverse investor base, which includes both private equity and strategic healthcare venture firms, provides the necessary stability to pursue long-term innovation and sustainable market expansion in the coming fiscal periods.
See full Rejoni company page
